Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

Blood

Volumn 122, Issue 19, 2013, Pages 3335-3339

  Gallipoli, Paolo ^a   Pellicano, Francesca ^a   Morrison, Heather ^a   Laidlaw, Kamilla ^a   Allan, Elaine K ^a,b   Bhatia, Ravi ^c   Copland, Mhairi ^a   Jørgensen, Heather G ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 3; NILOTINIB; PROTEIN CSF2RB; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; CHROMONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; INTERLEUKIN 3 RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BETA CHAIN; CANCER PATIENT; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INDOLES; INTERLEUKIN-3; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; NF-KAPPA B; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, INTERLEUKIN-3; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891689915     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-485607     Document Type: Article

References (25)

1. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657-3660.
2. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20): 5565-5572.
3. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501-1510.
4. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
5. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 1999; 96(22):12804-12809.
6. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol. 1986;136(12): 4487-4495.
7. Caux C, Favre C, Saeland S, Duvert V, Durand I, Mannoni P, Banchereau J. Potentiation of early hematopoiesis by tumor necrosis factor-alpha is followed by inhibition of granulopoietic differentiation and proliferation. Blood. 1991; 78(3):635-644.
8. Snoeck HW, Weekx S, Moulijn A, et al. Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma. J Exp Med. 1996;183(2): 705-710.
9. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72(9): 3666-3670.
10. O’Connell MA, Cleere R, Long A, O’Neill LA, Kelleher D. Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. J Biol Chem. 1995; 270(13):7399-7404.
11. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2): 103-113.
12. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011; 70(Suppl 1):i104-i108.
13. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398.
14. Zhang B, Ho YW, Huang Q, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4): 577-592.
15. Jiang Q, Crews LA, Barrett CL, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2013;110(3):1041-1046.
16. He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-alpha. Science. 2005; 310(5750):1022-1025.
17. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539.
18. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-665.
19. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680-1683.
20. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997;94(19):10057-10062.
21. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12(7):968-981.
22. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem. 1999;274(43): 30353-30356.
23. Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J, Miyajima A. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood. 1993;82(3):752-761.
24. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109(9):4016-4019.
25. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12(5):445-456.